Quantcast

Industry news that matters to you.  Learn more

New Molecular Imaging Biomarker Efficiently Demonstrates Malignant Prostate Tumors

Thomas Jefferson University in Philadelphia, PA and NuView Life Sciences of Park City, UT have entered into an exclusive licensing agreement for advancing the development of a new molecular imaging (MI) compound which identifies genomic expressions linked to prostate cancer (PC).

Quintiles Announces Suite of PI3K Biomarker Assays to Advance Oncology Therapies Targeting this Cancer Pathway

Quintiles today announced a comprehensive suite of biomarker assays to help bio pharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.